[{"orgOrder":0,"company":"MARATHON PHARMS","sponsor":"Aquestive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"MARATHON PHARMS","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"Buccal Film","sponsorNew":"MARATHON PHARMS \/ Marathon","highestDevelopmentStatusID":"12","companyTruncated":"MARATHON PHARMS \/ Marathon"}]

Find Clinical Drug Pipeline Developments & Deals by MARATHON PHARMS

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The proceeds will help to execute on advancing company's key clinical and commercial initiatives, including the resubmission of its NDA for FDA approval of lead product Libervant™ Buccal Film and ongoing clinical trial for AQST-108.

                          Brand Name : Libervant

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 23, 2020

                          Lead Product(s) : Diazepam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Recipient : Aquestive Therapeutics

                          Deal Size : $85.0 million

                          Deal Type : Agreement

                          blank